Fruzaqla Dosage
Generic name: FRUQUINTINIB 1mg
Dosage form: capsule
Drug classes: Multikinase inhibitors, VEGF/VEGFR inhibitors
Medically reviewed by Drugs.com. Last updated on Aug 2, 2024.
Recommended Dosage
The recommended dose of FRUZAQLA is 5 mg orally once daily for the first 21 days of each 28-day cycle until disease progression or unacceptable toxicity. Take FRUZAQLA with or without food at approximately the same time each day.
Swallow the FRUZAQLA capsule whole.
Take a missed dose if less than 12 hours have passed since the missed scheduled dose. Do not take two doses on the same day to make up for a missed dose.
Do not take an additional dose if vomiting occurs after taking FRUZAQLA but continue with the next scheduled dose.
Dosage Modifications for Adverse Reactions
The recommended dose reductions for adverse reactions are provided in Table 1.
Dose Level | [FRUZAQLA DOSE] |
---|---|
First dose reduction | 4 mg orally once daily |
Second dose reduction | 3 mg orally once daily |
Permanently discontinue FRUZAQLA in patients unable to tolerate 3 mg orally once daily.
The recommended dosage modifications for adverse reactions are provided in Table 2.
Adverse Reaction | Severity* | FRUZAQLA Dosage Modification |
---|---|---|
|
||
Hypertension | Grade 3 |
|
Grade 4 | Permanently discontinue FRUZAQLA. | |
Hemorrhagic Events | Grade 2 |
|
Grade 3 or Grade 4 | Permanently discontinue FRUZAQLA. | |
Hepatotoxicity | Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 3 times upper limit of normal (ULN) with total bilirubin less than or equal to 2 times ULN |
|
ALT or AST greater than 3 times ULN with concurrent total bilirubin greater than 2 times ULN (in the absence of cholestasis or hemolysis) | Permanently discontinue FRUZAQLA. | |
AST or ALT greater than 20 times ULN or bilirubin greater than 10 times ULN | Permanently discontinue FRUZAQLA. | |
Proteinuria | 2 grams or greater proteinuria in 24 hours |
|
Palmar-plantar erythrodysesthesia (PPE) | Grade 2 |
|
Grade 3 |
|
|
Other Adverse Reactions | Grade 3 |
|
Grade 4 | Discontinue FRUZAQLA. Consider resuming FRUZAQLA at the next lower dose level only if the toxicity is non-life threatening and fully resolves or recovers to Grade 1 and the potential benefit outweighs the risks. |
More about Fruzaqla (fruquintinib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.